Research: 2011–2015

🐀 = animal study      🧬 = genetics focus      📚 = systematic review / meta-analysis

Jump to: 2016–present | 2015 | 2014 | 2013 | 2012 | 2011 | 2000–2010 | 1974–1999 | Search site

2015

↑ back to top

Ali AK, Heran BS, Etminan M. Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study. Pharmacotherapy. 2015;35(7):687-695. doi:10.1002/phar.1612 | PubMed

📚 Belknap SM, Aslam I, Kiguradze T, et al. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis. JAMA Dermatol. 2015;151(6):600-606. doi:10.1001/jamadermatol.2015.36 | PubMed

Caruso D, Abbiati F, Giatti S, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74-79. doi:10.1016/j.jsbmb.2014.03.012 | PubMed

🐀 🧬 Chávez B, Ramos L, García-Becerra R, Vilchis F. Hamster SRD5A3 lacks steroid 5α-reductase activity in vitro. Steroids. 2015;94:41–50. doi:10.1016/j.steroids.2014.11.005 | PubMed

Chou CH, Lin CL, Lin MC, Sung FC, Kao CH. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. J Endocrinol Invest. 2015 Jul;38(7):799-805. doi:10.1007/s40618-015-0263-1 | PubMed

Descazeaud A, de La Taille A, Giuliano F, Desgrandchamps F, Doridot G. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia]. Prog Urol. 2015;25(3):115-127. doi:10.1016/j.purol.2014.12.003 | PubMed

Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2015;9(3):222-228. doi:10.1177/1557988314538445 | PubMed

Glina S, Roehrborn CG, Esen A, et al. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. J Sex Med. 2015;12(1):129-138. doi:10.1111/jsm.12714PubMed

🐀 Horvath K, Vultur F, Simon V, Voidazan S, Mühlfay G. Research on intraoperative iris behavior in rabbits treated with tamsulosin and finasteride. Hippokratia. 2015 Jan-Mar;19(1):20-4. PubMed | PMC full text

Irwig MS. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2015;22(3):248-253. doi:10.1097/MED.0000000000000158 | PubMed

Kang DW, Jeong HG, Kim HR, et al. Finasteride Induced Cerebral Venous Thrombosis. Journal of the Korean Neurological Association. 2015;33(3):238-240. PDF at ResearchGate

🐀 Kolasa-Wolosiuk A, Misiakiewicz-Has K, Baranowska-Bosiacka I, Gutowska I, Wiszniewska B. Androgen levels and apoptosis in the testis during postnatal development of finasteride-treated male rat offspring. Folia Histochem Cytobiol. 2015;53(3):236-48. doi:10.5603/fhc.a2015.0025 | PubMed

Lee MR, Loux-Turner JR, Oliveira K. Evaluation of the 5α-reductase inhibitor finasteride on reproduction and gonadal development in medaka, Oryzias latipes. Gen Comp Endocrinol. 2015 May 15;216:64-76. doi:10.1016/j.ygcen.2015.04.008 | PubMed

Lin WL, Hsieh YW, Lin CL, Sung FC, Wu CH, Kao CH. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clin Endocrinol (Oxf). 2015 Apr;82(4):503-8. doi:10.1111/cen.12599 | PubMed

🐀 Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2015;97:86‐94. doi:10.1016/j.neuropharm.2015.05.015 | PubMed

🐀 Livingstone DE, Barat P, Di Rollo EM, et al. 5α-Reductase type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents. Diabetes. 2015;64(2):447-458. doi:10.2337/db14-0249 | PubMed

Mirela M, Ioana P, Maria PG, Mihnea MC. Finasteride side effects and post-Finasteride syndrome in male androgenic alopecia. Journal of Mind and Medical Sciences. 2015;2(2):142–149. Open access

Mladenović D, Petronijević N, Stojković T, et al. Finasteride has regionally different effects on brain oxidative stress and acetylcholinesterase activity in acute thioacetamide-induced hepatic encephalopathy in rats. PLoS One. 2015 Aug 4;10(8):e0134434. doi:10.1371/journal.pone.0134434 | PubMed

Moore TJ. Finasteride and the Uncertainties of Establishing Harms. JAMA Dermatol. 2015 Jun;151(6):585-6. doi:10.1001/jamadermatol.2015.37 | PubMed

Narasimhalu CR. Randomized Questionnaire Based Case-Control Research Study on Evaluation of Sexual Function in Indian Patients Taking Oral Finasteride for Androgenetic Alopecia. Dermatol Ther (Heidelb). 2015;5(4):231-234. doi:10.1007/s13555-015-0084-3 | PubMed

Nasiri M, Nikolaou N, Parajes S, et al. 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. Endocrinology. 2015;156(8):2863–2871. doi:10.1210/en.2015-1149 | PubMed

Perez-Mora N, Velasco C, Bermüdez F. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men. Skinmed. 2015;13(3):179-183. PubMed

Stojanović N, Ignjatović I, Djenić N, Bogdanović D. Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. Srp Arh Celok Lek. 2015;143(5-6):284–289. doi:10.2298/sarh1506284s | PubMed

Tian HL, Zhao CX, Wu HY, et al. Finasteride reduces microvessel density and expression of vascular endothelial growth factor in renal tissue of diabetic rats. Am J Med Sci. 2015 Jun. 10.1097/MAJ.0000000000000451PubMed

Traish AM. The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being. Curr Sex Health Rep. 2015;7:210–219. doi:10.1007/s11930-015-0061-y

Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23(3):85-96. doi:10.1515/hmbci-2015-0015 | PubMed

Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Rev Endocr Metab Disord. 2015;16(3):177-198. doi:10.1007/s11154-015-9319-y | PubMed

2014

↑ back to top

Bauman TM, Sehgal PD, Johnson KA, et al. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate. 2014;74(9):923–932. doi:10.1002/pros.22810 | PubMed

Bissegger S, Martyniuk CJ, Langlois VS. Transcriptomic profiling in Silurana tropicalis testes exposed to finasteride. Gen Comp Endocrinol. 2014;203:137–145. doi:10.1016/j.ygcen.2014.01.018 | PubMed

Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727-733. doi:10.1016/j.juro.2013.09.059 | PubMed

🧬 Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers. 2014;29(4):e310–e316. doi:10.5301/jbm.5000095 | PubMed

Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014;2014:329456. doi:10.1155/2014/329456 | PubMed

Di Loreto C, La Marra F, Mazzon G, et al. Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. PLoS One. 2014;9(6):e100237. doi:10.1371/journal.pone.0100237 | PubMed | PMC full text

Duijnhoven RG, Straus SM, Souverein PC, et al. Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer Causes Control. 2014;25(11):1577-1582. doi:10.1007/s10552-014-0455-6 | PubMed

Famenini S, Gharavi NM, Beynet DP. Finasteride associated melasma in a Caucasian male. J Drugs Dermatol. 2014;13(4):484-486. PubMed | Journal site

Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828-1834. doi:10.1016/j.juro.2013.12.014 | PubMed

📚 Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554-1566. doi:10.1111/jsm.12525 | PubMed

Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.e3. doi:10.1016/j.jaad.2013.10.049 | PubMed

📚 Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014;25(2):156-161. doi:10.3109/09546634.2013.813011 | PubMed

Hogan C, Le Noury J, Healy D, Mangin D. One hundred and twenty cases of enduring sexual dysfunction following treatment. Int J Risk Saf Med. 2014;26(2):109-116. doi:10.3233/JRS-140617 | PubMed

Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150(12):1361-1363. doi:10.1001/jamadermatol.2014.1830 | PubMed

Irwig MS. Persistent Sexual and Nonsexual Adverse Effects of Finasteride in Younger Men. Sex Med Rev. 2014;2(1):24-35. doi:10.1002/smrj.19 | PubMed

Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351-1357. doi:10.1111/ijd.12060 | PubMed

🐀 Modol L, Casas C, Navarro X, et al. Neonatal finasteride administration alters hippocampal α4 and δ GABAAR subunits expression and behavioural responses to progesterone in adult rats. Int J Neuropsychopharmacol. 2014;17(2):259-273. doi:10.1017/S1461145713000989 | PubMed

Ryu HJ, Kwon DY. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia. Dermatol Surg. 2014;40(5):595-597. doi:10.1111/dsu.12458 | PubMed

Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring? J Clin Aesthet Dermatol. 2014;7(12):51-55. PubMed

🐀 Singh S, Moksha L, Sharma N, Titiyal JS, Biswas NR, Velpandian T. Development and evaluation of animal models for sex steroid deficient dry eye. J Pharmacol Toxicol Methods. 2014;70(1):29–34. doi:10.1016/j.vascn.2014.03.004 | PubMed

Traish AM, Guay AT, Zitzmann M. 5α-Reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014;20(3):73-80. doi:10.1515/hmbci-2014-0025 | PubMed

Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367-379. doi:10.4111/kju.2014.55.6.367 | PubMed

Tsuji Y, Nakayama T, Bono K, Kitamura M, Imafuku I. [Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan]. Rinsho Shinkeigaku. 2014;54(5):423-8. Japanese. doi:10.5692/clinicalneurol.54.423 | PubMed

Varothai, S, Bergfeld, WF. Androgenetic Alopecia: An Evidence-Based Treatment Update. Am J Clin Dermatol.2014;15:217–230. doi:10.1007/s40257-014-0077-5

Yim E, Nole KL, Tosti A. 5α-Reductase inhibitors in androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):493-498. doi:10.1097/MED.0000000000000112 | PubMed

2013

↑ back to top

Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013;190(5):1811-1814. doi:10.1016/j.juro.2013.04.132 | PubMed

Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013;185(10):E455-E456. doi:10.1503/cmaj.109-4488 | PubMed

Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12(1):81-90. doi:10.1517/14740338.2013.742885 | PubMed

Irwig MS. Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report. Alcohol Clin Exp Res. 2013;37(11):1823-1826. doi:10.1111/acer.12177 | PubMed

Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Singh S. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor – Dutasteride. J Clin Pharm Ther. 2013 Oct;38(5):405-15. doi:10.1111/jcpt.12080 | PubMed

Melcangi RC, Caruso D, Abbiati F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013;10(10):2598-2603. doi:10.1111/jsm.12269 | PubMed

Millsop JW, Heller MM, Eliason MJ, Murase JE. Dermatological medication effects on male fertility. Dermatol Ther. 2013;26(4):337–346. doi:10.1111/dth.12069 | PubMed

🐀 Mòdol L, Darbra S, Vallèe M, Pallarès M. Alteration of neonatal Allopregnanolone levels affects exploration, anxiety, aversive learning and adult behavioural response to intrahippocampal neurosteroids. Behav Brain Res. 2013;241:96-104. doi:10.1016/j.bbr.2012.11.043 | PubMed

Motofei IG, Rowland DL, Georgescu SR, et al. A pilot study on the sexual side effects of finasteride as related to hand preference for men undergoing treatment of male pattern baldness. BJU Int. 2013;111(4 Pt B):E221-6. doi:10.1111/j.1464-410X.2012.11580.x | PubMed

Nusbaum AG, Rose PT, Nusbaum BP. Nonsurgical therapy for hair loss. Facial Plast Surg Clin North Am. 2013 Aug;21(3):335-42. doi:10.1016/j.fsc.2013.04.003 | PubMed

Şalvarci A, Istanbulluoğlu O. Secondary infertility due to use of low-dose finasteride. Int Urol Nephrol. 2013;45(1):83-85. doi:10.1007/s11255-012-0315-9 | PubMed

Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100(6):1542–1546. doi:10.1016/j.fertnstert.2013.07.2000 | PubMed

[Comment] Hotaling JM. Finasteride and male infertility: a case for prospective collaborative research databases? Fertil Steril. 2013 Dec;100(6):1528-9. doi:10.1016/j.fertnstert.2013.08.023 | PubMed

Stanczyk FZ, Azen CG, Pike MC. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10–16. doi:10.1016/j.jsbmb.2013.02.015 | PubMed

[Comment] Traish AM, Morgentaler A. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:462. doi:10.1016/j.jsbmb.2013.06.013 | PubMed

📚 Trost L, Saitz TR, Hellstrom WJ. Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review. Sex Med Rev. 2013;1(1):24-41. doi:10.1002/smrj.3 | PubMed

🐀 Zhang MG, Wang XJ, Shen ZJ, Gao PJ. Long-term oral administration of 5α-reductase inhibitor attenuates erectile function by inhibiting autophagy and promoting apoptosis of smooth muscle cells in corpus cavernosum of aged rats. Urology. 2013;82(3):743.e9–743.e7.43E15. doi:10.1016/j.urology.2013.02.045 | PubMed

🐀 Zhao XF, Yang Y, Wang W, Qiu Z, Zhang P, Wang B. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Chin Med J (Engl). 2013;126(4):711–715. doi:10.3760/cma.j.issn.0366-6999.20122496 | PubMed

2012

↑ back to top

Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol. 2012;2012:530121. doi:10.1155/2012/530121 | PubMed

Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia. 2012;44 Suppl 1:836-837. doi:10.1111/j.1439-0272.2011.01214.x | PubMed

Corona G, Rastrelli G, Maseroli E, et al. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. J Endocrinol Invest. 2012;35(10):915-920. doi:10.3275/8510 | PubMed

Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24;379(9821):1103-11. doi:10.1016/S0140-6736(11)61619-X | PubMed

🐀 Garcia PV, Barbieri MF, Perobelli JE, et al. Morphometric-stereological and functional epididymal alterations and a decrease in fertility in rats treated with finasteride and after a 30-day post-treatment recovery period. Fertil Steril. 2012 Jun;97(6):1444-51. doi:10.1016/j.fertnstert.2012.03.025 | PubMed

Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220-1223. doi:10.4088/JCP.12m07887 | PubMed

Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012 Nov;9(11):2927-32. doi:10.1111/j.1743-6109.2012.02846.x | PubMed

[Comment] Canguven O, Talib RA. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2013;10(5):1441. doi:10.1111/jsm.12089 | Journal site

🐀 Jarvi K. Hairless or fertile? Finasteride leads to epididymal changes and infertility in rats. Fertil Steril. 2012 Jun;97(6):1298. doi:10.1016/j.fertnstert.2012.04.016 | PubMed

Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052-1055. doi:10.1111/j.1742-1241.2012.03010.x | PubMed

Kuehn BM. Prostate, baldness drugs linked to sexual dysfunction. JAMA. 2012;307(18):1903. doi:10.1001/jama.2012.4488 | PubMed

La Marra F, Di Loreto C, Mazzon G, et al. Preliminary evidence of a peculiar hormonal profile in men with adverse effects after use of finasteride against androgenetic alopecia. Am J Pathol. 2012;181:S8. doi:10.1016/S0002-9440(12)00566-4

Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62-65. doi:10.4103/2229-5178.93496

🐀 Oztekin CV, Gur S, Abdulkadir NA, Lokman U, Akdemir AÖ, Cetinkaya M, Hellstrom WJ. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med. 2012;9(7):1773–1781. doi:10.1111/j.1743-6109.2012.02759.x | PubMed

Ricci G, Martinelli M, Luppi S, et al. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 2012;11(12):1511–1513. doi:10.1111/dth.12069 | PubMed

Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012;18(6):965–975. doi:10.4158/EP12108.RA | PubMed

Tresch S, Cozzio A, Kamarashev J, et al. T cell-mediated acute localized exanthematous pustulosis caused by finasteride. J Allergy Clin Immunol. 2012 Feb;129(2):589-94. doi:10.1016/j.jaci.2011.07.033 | PubMed

Zhang MG, Wu W, Zhang CM, et al. Effects of oral finasteride on erectile function in a rat model. J Sex Med. 2012 May;9(5):1328-36. doi:10.1111/j.1743-6109.2012.02661.x | PubMed

2011

↑ back to top

Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011 Sep;52(9):632-6. doi:10.4111/kju.2011.52.9.632 | PubMed

Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasteride-associated male infertility. Fertil Steril. 2011;95(5):. doi:10.1016/j.fertnstert.2010.12.001 | PubMed

Goldstein I. An old problem with a new cause-5 alpha reductase inhibitors and persistent sexual dysfunction. J Sex Med. 2011;8(7):1829–1831. doi:10.1111/j.1743-6109.2011.02368.x | PubMed

[Comment] Uribe JF. Persistent sexual dysfunction and 5 alpha reductase inhibitors. J Sex Med. 2012;9(9):2475. doi:10.1111/j.1743-6109.2012.02676.x | PubMed

Gude D. Finasteride and male fertility. J Hum Reprod Sci. 2011 May;4(2):101-2. doi:10.4103/0974-1208.86093 | PubMed | PMC full text

Hwang TIS. Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Urological Science. 2011;22(1):14-18. doi:10.1016/S1879-5226(11)60003-1

Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-1753. doi:10.1111/j.1743-6109.2011.02255.x | PubMed

🐀 Kolasa A, Marchlewicz M, Wenda-Różewicka L, Wiszniewska B. DHT deficiency perturbs the integrity of the rat seminiferous epithelium by disrupting tight and adherens junctions. Folia Histochem Cytobiol. 2011;49(1):62-71. doi:10.5603/fhc.2011.0010 | PubMed

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011 Aug;108(3):388-94. doi:10.1111/j.1464-410X.2011.10195.x | PubMed

🐀 Paris JJ, Brunton PJ, Russell JA, Walf AA, Frye CA. Inhibition of 5α-reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progestogen milieu of juvenile rat offspring. J Neuroendocrinol. 2011;23(11):1079-1090. doi:10.1111/j.1365-2826.2011.02219.x | PubMed

🐀 Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–3074. doi:10.1111/j.1743-6109.2011.02425.x | PubMed

Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455–461. doi:10.1111/j.1529-8019.2011.01441.x | PubMed

Santo Domingo D, Stevenson ML, Auerbach J, Lerman J. Finasteride-induced pseudoporphyria. Arch Dermatol. 2011;147(6):747‐748. doi:10.1001/archdermatol.2011.144 | PubMed

Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872-884. doi:10.1111/j.1743-6109.2010.02157.x | PubMed

Tu HY, Zini A. Finasteride-induced secondary infertility associated with sperm DNA damage. Fertil Steril. 2011;95(6):2125.e13–2125.e14. doi:10.1016/j.fertnstert.2010.12.061 | PubMed

Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011 Jul;37(7):1351-4. doi:10.1016/j.jcrs.2011.04.013 | PubMed

Bibliographies: 2016–present | 2011–2015 | 2000–2010 | 1974–1999 | Search site